You are here:

sacubitril/valsartan (Entresto)

Advice

following a full submission

sacubitril/valsartan (Entresto®) is accepted for use within NHS Scotland.

Indication under review: in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.

Sacubitril/valsartan, compared to an angiotensin-converting enzyme inhibitor, significantly reduced rates of the composite outcome of cardiovascular death and hospitalisation for heart failure, rates of the component outcomes and of all cause mortality.

Drug Details

Drug Name: sacubitril/valsartan (Entresto)
SMC Drug ID: 1132/16
Manufacturer: Novartis Pharmaceuticals UK Ltd
Indication: In adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.
BNF Category:
Sub Category: 2.5 Hypertension and heart failure
Submission Type: Full submission
Status: Accepted
Date Advice Published: 7 March 2016

Back